Question 1

What is Ovid Therapeutics's P/S ratio?

Accepted Answer

Ovid Therapeutics (OVID) P/S ratio is 24.3× as of July 27, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month revenue, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/S ratio calculated?

Accepted Answer

P/S = Market Capitalisation ÷ Trailing Twelve-Month (TTM) Revenue, or equivalently Share Price ÷ TTM Revenue Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/S ratio?

Accepted Answer

The price-to-sales (P/S) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) revenue. It is calculated as market cap ÷ TTM revenue (equivalent to share price ÷ TTM revenue per share). Because the denominator (revenue) cannot be negative, P/S is widely used to value unprofitable or pre-profit companies and to make cross-sector comparisons.

Question 4

What is a good P/S ratio for Ovid Therapeutics?

Accepted Answer

A "good" P/S depends heavily on profit margin and growth: software and other high-margin businesses often command 5–15× sales, while low-margin retailers and commodity producers typically trade below 1×. Compare against sector peers rather than absolute thresholds. For Ovid Therapeutics specifically, the relevant sector benchmark is the current sector median of 3.4×.

Question 5

Is Ovid Therapeutics's P/S ratio high or low?

Accepted Answer

Ovid Therapeutics's P/S ratio of 24.3× is below its own 5-year average of 274.2× and above the sector median of 3.4×. That places the current reading at the 29th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Ovid Therapeutics's historical P/S ratio range?

Accepted Answer

In the available daily series, Ovid Therapeutics (OVID) P/S ratio has ranged from a low of 0.8× in 2022 to a high of 2222.4× in 2023. The 5-year average is 274.2× and the 5-year median is 96.1×.

Question 7

What was Ovid Therapeutics's P/S ratio in 2025?

Accepted Answer

Ovid Therapeutics (OVID) P/S ratio at the end of 2025 was 18.4×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month revenue figure available at that date.

Question 8

Why does Ovid Therapeutics's P/S ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (revenue). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$133M	$7.25M	18.4×	-98.8×	Dec 31, 2025
2024	$66.3M	$566K	117.1×	-463.5×	Dec 31, 2024
2023	$228M	$392K	580.6×	+493.4×	Dec 31, 2023
2022	$131M	$1.5M	87.2×	+86.2×	Dec 31, 2022
2021	$217M	$208M	1.0×	-10.5×	Dec 31, 2021
2020	$145M	$12.6M	11.5×	—	Dec 31, 2020
2019	$204M	$0.00	—	—	Dec 31, 2019
2018	$59.6M	$0.00	—	—	Dec 31, 2018
2017	$243M	$0.00	—	—	Dec 31, 2017
2016	$240M	$0.00	—	—	Dec 31, 2016


AptarGroup (ATR)	2.1×
Becton, Dickinson and (BDX)	2.1×
Quest Diagnostics (DGX)	2.0×
Charles River (CRL)	1.9×
IQVIA (IQV)	1.7×
GE HealthCare (GEHC)	1.6×
Labcorp Holdings (LH)	1.6×
Solventum (SOLV)	1.4×
HCA Healthcare (HCA)	1.1×
Viatris (VTRS)	1.1×
UnitedHealth Group (UNH)	0.8×
Baxter International (BAX)	0.8×
DaVita (DVA)	0.7×
Henry Schein (HSIC)	0.6×
Universal Health Services (UHS)	0.6×
Elevance Health (ELV)	0.4×
Teladoc Health (TDOC)	0.4×
Molina Healthcare (MOH)	0.3×
McKesson (MCK)	0.3×
Cigna (CI)	0.3×
CVS Health (CVS)	0.2×
Cardinal Health (CAH)	0.2×
Cencora (COR)	0.2×
Humana (HUM)	0.2×
Centene (CNC)	0.1×

P/S Ratio for Ovid Therapeutics (OVID) 2020-2026

P/S Ratio daily chart for Ovid Therapeutics (OVID)

Historical P/S Ratio for Ovid Therapeutics (OVID) from 2016 to 2025

About P/S Ratio at Ovid Therapeutics (OVID)

Ovid Therapeutics P/S Ratio by Year

Ovid Therapeutics P/S Ratio 2025: 18.4×

Ovid Therapeutics P/S Ratio 2024: 117.1×

Ovid Therapeutics P/S Ratio 2023: 580.6×

Ovid Therapeutics P/S Ratio 2022: 87.2×

Ovid Therapeutics P/S Ratio 2021: 1.0×

Sector peers by P/S Ratio — chart

Sector peers by P/S Ratio — table

Frequently asked questions

Ovid Therapeutics (OVID) Key Financials